Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:21:28 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:IMVT - IMMUNOVANT INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IMVT - Q2.017.51·20.290.117.91-0.37-2.01,030.218,0439,17018.49  18.67  17.8434.47  12.7219:20:10May 2915 min RT 2¢

Recent Trades - Last 10 of 9170
Time ETExPriceChangeVolume
19:20:10Q17.70-0.5850
16:34:01Q17.91-0.371,400
16:32:58Q17.91-0.3784,236
16:09:35Q17.79-0.491
16:04:12Q17.91-0.371
16:04:10Q17.91-0.371
16:04:10Q17.91-0.371
16:04:07Q17.91-0.371
16:02:34Q17.91-0.37340
16:02:34Q17.91-0.37182

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-29 07:00U:IMVTNews ReleaseImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
2025-04-21 07:00U:IMVTNews ReleaseImmunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
2025-03-19 07:45U:IMVTNews ReleaseImmunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
2025-03-18 16:32U:IMVTNews ReleaseImmunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
2025-02-06 06:30U:IMVTNews ReleaseImmunovant Reports Financial Results for the Quarter Ended December 31, 2024
2025-01-13 08:00U:IMVTNews ReleaseImmunovant Announces $450 Million Private Placement
2024-11-07 06:30U:IMVTNews ReleaseImmunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
2024-10-29 06:30U:IMVTNews ReleaseImmunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
2024-09-09 07:00U:IMVTNews ReleaseRoivant Provides Update on Graves' Disease Development Program
2024-09-09 03:55U:IMVTNews ReleaseImmunovant Provides Update on Graves' Disease Development Program
2024-09-05 06:30U:IMVTNews ReleaseImmunovant to Host Graves' Disease Program Update on September 9, 2024
2024-08-06 16:05U:IMVTNews ReleaseImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024